Indacaterol/mometasone

Indacaterol/mometasone
Combination of
Indacaterol	Beta-2 adrenergic receptor agonist
Mometasone	Corticosteroid
Clinical data
Trade names	Atectura Breezhaler, Bemrist Breezhaler
Other names	QMF149, IND/MF
License data	EU EMA: by INN;
Routes of; administration	Inhalation
ATC code	R03AK14 (WHO) ;
Legal status
Legal status	CA: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Identifiers
KEGG	D11862;

Indacaterol/mometasone, sold under the brand name Atectura Breezhaler among others, is a fixed-dose combination medication for the treatment of asthma in adults and adolescents twelve years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta₂ agonists.^[2]

The most common side effects include worsening of asthma and nasopharyngitis (inflammation in the nose and throat).^[2] Other common side effects include upper respiratory tract infection (nose and throat infections) and headache.^[2] Indacaterol/mometasone was approved for medical use in the European Union in May 2020,^[2] and in Japan in June 2020.^[3]

References

^ "Regulatory Decision Summary - Atectura Breezhaler". Health Canada. 23 October 2014. Retrieved 7 June 2022.
^ ^a ^b ^c ^d ^e "Atectura Breezhaler EPAR". European Medicines Agency (EMA). 24 March 2020. Retrieved 23 June 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^ "Novartis receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare, offering Japanese patients a broad range of novel treatment options". Novartis (Press release). 29 June 2020. Archived from the original on 26 July 2020. Retrieved 25 July 2020.

External links

"Indacaterol mixture with mometasone furoate". Drug Information Portal. U.S. National Library of Medicine.

This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.

[1] "Regulatory Decision Summary - Atectura Breezhaler". Health Canada. 23 October 2014. Retrieved 7 June 2022.

[Atectura_Breezhaler_EPAR-2] "Atectura Breezhaler EPAR". European Medicines Agency (EMA). 24 March 2020. Retrieved 23 June 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[3] "Novartis receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare, offering Japanese patients a broad range of novel treatment options". Novartis (Press release). 29 June 2020. Archived from the original on 26 July 2020. Retrieved 25 July 2020.

[1]

[2]

[3]